Investigation of the effect of cryoprecipitate (blood plasma product that can help blood to clot) transfusion on coagulation abnormalities after open heart, aortic surgeries

Fibrinogen recovery and FIBTEM changes after cryoprecipitate transfusion in patients undergoing aortic surgery involving deep hypothermic circulatory arrest

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612001063808

Enrollment

Registered

2012-10-04

Start date

2009-12-27

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Cryoprecipitate may be used as haemostatic agent in patients with bleeding following on-pump aortic surgery with deep hypothermic circulatory arrest (DHCA). Its effect on plasma fibrinogen concentration and fibrin clot quality has not been reported to date. Standard coagulation laboratory and ROTEM parameters including clotting time (CT), alpha angle (a), clot amplitude A10 (amplitude at 10 minutes after clotting initiation) in extrinsically-activated EXTEM and fibrin-based FIBTEM were evaluated before and after cryoprecipitate transfusion.

Interventions

1. If considered appropriate clinically and with laboratory (FIBTEM A10 result), 10 units of cryoprecipitate (350-400ml /10 units) are transfused 5-10 minutes after protamine administration at the end of cardiopulmonary bypass (CPB) weaning. 2. 10 units of cryoprecipitates are given over 20-30 minutes. 3. 10 minutes after completion of cryoprecipitate transfusion, the following test are done. - platelet count, PT, INR, aPTT, fibrinogen - ROTEM parameters : coagulation time (CT), alpha angle,

Study design

Allocation

Non-randomised trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

Elective or emergency aortic surgery involving deep hypothermic circulatory arrest (DHCA) during cardiopulmonary bypass (CPB)

Exclusion criteria

Patients were excluded from the study if they revealed severe hypofibrinogenemia preoperatively, indicated by serum fibrinogen < 50mg/dl or FIBTEM < 1, or if the patients were not indicated to receive cryoprecipitate transfusion after protamine reversal.

Outcome results